Endovascular Transcatheter Aortic Valve Replacement Outcomes in Hypertrophic Cardiomyopathy: Insights from the National Inpatient Sample (2014–2018)
Cardiology · 2023
DOI: 10.1159/000530043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology, 2023. Verfasst von Rohit Vyas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, University of Toledo, Toledo, Ohio, USA. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Cardiomyopathy, Hypertrophic, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Background
Outcomes of patients with hypertrophic cardiomyopathy (HCM) following transcatheter aortic valve replacement (TAVR) remain largely unknown.
Objectives
This study sought to assess the clinical characteristics and outcomes of HCM patients following TAVR.
Methods
We queried the National Inpatient Sample from 2014 to 2018 for TAVR hospitalizations with and without HCM, creating a propensity-matched cohort to compare outcomes.
Results
207,880 patients that underwent TAVR during the study period, 810 (0.38%) had coexisting HCM. In the unmatched population, TAVR patients with HCM compared to those without HCM, were more likely to be female, had a higher prevalence of heart failure, obesity, cancer, and history of pacemaker/implantable cardioverter defibrillation, and were more likely to have nonelective and weekend admissions (p for all <0.05). TAVR patients without HCM had higher prevalence of coronary artery disease, prior percutaneous coronary intervention, prior coronary artery bypass grafting, and peripheral arterial disease compared to their counterparts (p for all <0.05). In the propensity-matched cohort, TAVR patients with HCM had significantly higher incidence of in-hospital mortality, acute kidney injury/hemodialysis, bleeding complications, vascular complications, permanent pacemaker requirement, aortic dissection, cardiogenic shock, and mechanical ventilation requirement.
Conclusion
Endovascular TAVR in HCM patients is associated with an increased incidence of in-hospital mortality and procedural complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, University of Toledo, Toledo, Ohio, USA.
- Department of Cardiology, Reading Hospital-Tower Health System, West Reading, Pennsylvania, USA.
- Division of Medicine, Forrest General Hospital, Hattiesburg, Mississippi, USA.
- Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA.
- Division of Cardiovascular Medicine, ProMedica Toledo Hospital, Toledo, Ohio, USA.
Zitieren
APA
Vyas, R., Nazir, S., Ahuja, K. R., Minhas, A. M. K., Elzanaty, A., Mir, T., & Sheikh, M. (2023). Endovascular Transcatheter Aortic Valve Replacement Outcomes in Hypertrophic Cardiomyopathy: Insights from the National Inpatient Sample (2014–2018). Cardiology. https://doi.org/10.1159/000530043
Vancouver
Vyas R, Nazir S, Ahuja KR, Minhas AMK, Elzanaty A, Mir T, et al. Endovascular Transcatheter Aortic Valve Replacement Outcomes in Hypertrophic Cardiomyopathy: Insights from the National Inpatient Sample (2014–2018). Cardiology. 2023. doi:10.1159/000530043
BibTeX
@article{Vyas2023,
author = {Vyas, Rohit and Nazir, Salik and Ahuja, Keerat Rai and Minhas, Abdul Mannan Khan and Elzanaty, Ahmed and Mir, Tanveer and Sheikh, Mujeeb},
title = {Endovascular Transcatheter Aortic Valve Replacement Outcomes in Hypertrophic Cardiomyopathy: Insights from the National Inpatient Sample (2014–2018)},
journal = {Cardiology},
year = {2023},
doi = {10.1159/000530043}
}
EUVIMED